Thanks, Idit, but you didn’t answer oc631’s question about whether the FDA will entertain an early NDA submission—i.e. a submission based on phase-2 data—for the genotype-2/3 subgroup.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.